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D
iabetes rates are increasing around the world,
mainly driven by increasing levels of obesity
(1). The dilemma for diabetes prevention is that
the main risk factor—obesity—is a product of
our modern lifestyle (the so-called obesogenic environ-
ment) (2). Immediate prospects for changing the environ-
ment to reverse rising obesity levels are not promising,
and there is a need to consider other options for prevent-
ing diabetes.
One of these options—vitamin D—is addressed in the
article by Forouhi et al. (3) in the current issue of
Diabetes. The sun is the primary source of vitamin D,
which is synthesized endogenously in skin to produce
cholecalﬁcerol (vitamin D3), although a small proportion
(20%) of vitamin D comes through diet from a limited
range of foods (in the form of ergocalciferol [vitamin D2]
and vitamin D3) (4). The main marker of vitamin D status
is the metabolite 25-hydroxyvitamin D [25(OH)D], which is
synthesized in the liver. The epidemiology of vitamin D
status is inverse to that of diabetes, since blood levels of
25(OH)D decline with age and are lower in populations
with increased skin pigmentation, such as African Ameri-
cans and South Asians, and in people with obesity, while
diabetes increases with age and obesity and is higher in
these ethnic groups (5).
Animal studies published nearly 30 years ago identiﬁed
a pancreatic receptor to the active metabolite (1,25-dihy-
droxyvitamin D) (6) and showed that vitamin D deﬁciency
decreased insulin secretion (7). Since then, numerous
human studies of vitamin D and type 2 diabetes have been
published, but the quality of these studies is mixed (8).
Many are case-control studies ﬂawed by the measurement
of 25(OH)D status on blood samples collected after diabe-
tes diagnosis. Several population-based cross-sectional
studies have been published showing inverse associations
between 25(OH)D and undiagnosed diabetes risk, includ-
ing two large national surveys (9,10), but this study design
provides only moderate evidence regarding causation be-
cause of the simultaneous measurement of 25(OH)D and
diabetes status. Stronger evidence comes from prospec-
tive studies, of which there have been two that show
inverse associations between dietary vitamin D and diabe-
tes risk (11,12); however, these studies are limited because
they did not assess the major nondietary component of
vitamin D from sun exposure.
The potentially strongest evidence comes from interven-
tion studies. Again, there are limitations with these be-
cause of small sample sizes and short intervention time
periods. Only three intervention studies had more than 100
participants and also administered vitamin D for long
periods (2–3 years). One study did not ﬁnd any effect from
a vitamin D3 dose of 2,000 IU/day but had only 25 people
on this dose (13). Another was a post hoc analysis of a trial
designed for bone-related outcomes that found that 700
IU/day of vitamin D3 (combined with calcium) decreased
homeostasis model assessment of insulin resistance in
participants with impaired glucose tolerance but not in
those with normal fasting glucose (14). The largest sample
to date of 33,951 women in the Women’s Health Initiative
study did not observe any effect from vitamin D (15).
Again, there are major limitations with this study due to
the low vitamin D3 dose of 400 IU/day, which only in-
creases blood 25(OH)D levels by about 7 nmol/l (16);
less-than-ideal compliance; and the presence of contami-
nation, since control subjects were able to take vitamin D.
In the absence of well-designed clinical trials, the stron-
gest evidence to date is provided by cohort studies com-
paring baseline measures of blood 25(OH)D (which reﬂect
vitamin D status from both sun and dietary sources) and
subsequent glycemic status. The study by Forouhi et al.
provides such evidence from an English cohort in the town
of Ely by showing that baseline serum 25(OH)D levels are
inversely associated with glucose and insulin levels col-
lected 10 years later (3). These ﬁndings conﬁrm recent
results from a Finnish cohort study showing an inverse
association between baseline serum 25(OH)D and 17-year
risk of type 2 diabetes, which was attenuated after adjust-
ment for confounders (17). Together, the two articles
provide strong evidence that low vitamin D status predicts
hyperglycemia. In addition, the current article provides
new prospective evidence that low levels of vitamin D also
predict hyperinsulinemia, a ﬁnding that conﬁrms previous
cross-sectional studies (9,18) and suggests that vitamin D
may act to prevent type 2 diabetes by decreasing insulin
resistance, although it may also inhibit insulin secretion
(18).
The strengths of the Ely study, in addition to its pro-
spective design and use of 25(OH)D to measure vitamin D
status, include its community-based sampling, which in-
creases the generalizability of the results, and the control-
ling of the most important confounders (obesity and
physical activity) in statistical analyses. Its limitations are
its relatively small sample size (n  524) and the 50% loss
to follow-up after 10 years. The authors report that partic-
ipants included in the 10-year follow-up analyses were
healthier at baseline than those excluded, and as they
state, this is likely to have resulted in a more conservative
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mic status.
Despite evidence from the current article (3) and the
Finnish study (17), doubts still remain about whether low
vitamin status is a cause of type 2 diabetes. Further cohort
studies are required, assessing baseline vitamin D status
using blood 25(OH)D to be sure that the Ely and Finnish
studies are not false-positive results. Glucose clamp stud-
ies are also required because we are still not sure of the
mechanism inﬂuenced by vitamin D—whether it is insulin
resistance, secretion, or both. But most importantly, given
that nearly three decades have passed since the ﬁrst
studies linking vitamin D with insulin metabolism (6,7),
well-designed clinical trials of the effect of vitamin D
supplementation on glycemia status and diabetes risk are
urgently required to settle this question. And they need to
prevent past mistakes. In particular, the vitamin D dose
given in such trials needs to be high enough—above 2,000
IU per day (19)—to raise blood 25(OH)D levels above 80
nmol/l because diabetes risk is lowest at this level (9,20).
If well-designed trials are carried out and conﬁrm a
protective effect from vitamin D, it could be used by the
general population as a simple and cheap solution to help
prevent the diabetes epidemic.
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